Početna › Leukemija › Massachusetts
Kliničke studije za Leukemija u državi Massachusetts
28 studija za Leukemija traži sudionike na lokacijama u državi Massachusetts.
Gradovi u državi Massachusetts
Službeni tekst studije (engleski)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT04996875Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Boston
U tijeku regrutacijaFaza 3
Od 18 do 18 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT07249346CIML NK Cells With Venetoclax for AML
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 do 90 godina · Oba spola · Ažurirano 26. kol 2026. · NCT07439211Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Massachusetts, Worcester
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT06001788ALL Backbone in AYAs
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 2
Od 18 do 51 godina · Oba spola · Ažurirano 17. kol 2026. · NCT07227584Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
- Mass General Brigham Cancer Institute, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 27. srp 2026. · NCT07671209Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 16. srp 2026. · NCT06469307Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 19 do 110 godina · Oba spola · Ažurirano 29. lip 2026. · NCT02012699A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 12 godina i više · Oba spola · Ažurirano 17. lip 2026. · NCT04024761Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. lip 2026. · NCT06138587A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 17. lip 2026. · NCT05475925A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. svi 2026. · NCT03219450Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 18. svi 2026. · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 30. tra 2026. · NCT04256317Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 21. tra 2026. · NCT05646576Shwachman Diamond Syndrome Registry and Study
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 6. tra 2026. · NCT06056908Revumenib in Combination With 7+3 + Midostaurin in AML
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 do 75 godina · Oba spola · Ažurirano 25. ožu 2026. · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. ožu 2026. · NCT05735184Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 11. velj 2026. · NCT06644183A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 5. velj 2026. · NCT07148180Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 15. pro 2025. · NCT07052695SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 28. lis 2025. · NCT03452774I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2025. · NCT05842603HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2025. · NCT06487247Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.